tradingkey.logo
tradingkey.logo
Suchen

Sonoma Pharmaceuticals Inc

SNOA
Zur Watchlist hinzufügen
1.210USD
0.0000.00%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
2.09MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Sonoma Pharmaceuticals Inc Unternehmen

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Sonoma Pharmaceuticals Inc Informationen

BörsenkürzelSNOA
Name des UnternehmensSonoma Pharmaceuticals Inc
IPO-datumJan 26, 2007
CEOTrombly (Amy)
Anzahl der mitarbeiter168
WertpapierartOrdinary Share
GeschäftsjahresendeJan 26
Addresse5445 Conestoga Court, Suite 150
StadtBOULDER
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl80301
Telefon18007599305
Websitehttps://sonomapharma.com/
BörsenkürzelSNOA
IPO-datumJan 26, 2007
CEOTrombly (Amy)

Führungskräfte von Sonoma Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay E. Birnbaum, Ph.D.
Dr. Jay E. Birnbaum, Ph.D.
Independent Director
Independent Director
286.00
-0.35%
Mr. Jerry G. Mclaughlin
Mr. Jerry G. Mclaughlin
Lead Independent Director
Lead Independent Director
--
--
Mr. Philippe Weigerstorfer
Mr. Philippe Weigerstorfer
Independent Director
Independent Director
--
--
Ms. Amy Trombly
Ms. Amy Trombly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jerry Dvonch
Mr. Jerry Dvonch
Chief Financial Officer
Chief Financial Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Sonoma Pharmaceuticals Inc?

Die fünf größten Anteilseigner von Sonoma Pharmaceuticals Inc sind: Dr. Jay E. Birnbaum, Ph.D.

Wie viele Institutionen halten Anteile an Sonoma Pharmaceuticals Inc (SNOA)?

Mit Stand vom 2026Q1 halten 40 Institutionen Anteile an Sonoma Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 127.80K, was 3.68% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -34692.00 gestiegen.

Was ist die größte Einnahmequelle von Sonoma Pharmaceuticals Inc?

Am 2026Q1 erzielte das Geschäft mit Human Care für Sonoma Pharmaceuticals Inc den höchsten Umsatz in Höhe von 3.86M, was 88.83% des Gesamtumsatzes entspricht.